Interferon-β exacerbates Th17-mediated inflammatory disease

Trends in Immunology

Volumn 32, Issue 6, 2011, Pages 272-277

  Axtell, Robert C ^a   Raman, Chander ^b   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER;

HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ULCERATIVE COLITIS;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INTERFERON-BETA; MODELS, IMMUNOLOGICAL; TH17 CELLS;

EID: 79957765659     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.03.008     Document Type: Review

References (76)

1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B: Biol. Sci. 1957, 147:258-267.
2. Schwid S.R., Panitch H.S. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin. Ther. 2007, 29:2031-2048.
3. Rio J., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 2006, 59:344-352.
4. Warabi Y., et al. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 2007, 252:57-61.
5. Wang A.G., et al. Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon beta-1a in Chinese patients. Jpn. J. Ophthalmol. 2006, 50:537-542.
6. Shimizu Y., et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J. Neurol. 2008, 255:305-307.
7. Pender M.P. Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?. Brain 2009, 132:3196-3198.
8. Axtell R.C., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
9. Martin-Saavedra F.M., et al. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 2008, 45:4008-4019.
10. Galligan C.L., et al. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult. Scler. 2010, 16:1458-1473.
11. Benveniste E.N., Qin H. Type I interferons as anti-inflammatory mediators. Sci. STKE 2007, pe70.
12. Bennett L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
13. van der Pouw Kraan T.C., et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 2007, 66:1008-1014.
14. van der Fits L., et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J. Invest. Dermatol. 2004, 122:51-60.
15. Shimizu J., et al. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75:1423-1427.
16. Palace J., et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 2010, 67:1016-1017.
17. Uzawa A., et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur. J. Neurol. 2010, 17:672-676.
18. Prinz M., Kalinke U. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol. Med. 2010, 16:379-386.
19. Prinz M., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.
20. Guo B., et al. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 2008, 118:1680-1690.
21. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
22. Teige I., et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 2003, 170:4776-4784.
23. Tigno-Aranjuez J.T., et al. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J. Immunol. 2009, 183:5654-5661.
24. Gao X., et al. Adjuvant treatment suppresses IL-17 production by T cell-independent myeloid sources in nonobese diabetic mice. Mol. Immunol. 2010, 47:2397-2404.
25. Durelli L., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol. 2009, 65:499-509.
26. Ramgolam V.S., et al. IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 2009, 183:5418-5427.
27. Hesse D., Sorensen P.S. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur. J. Neurol. 2007, 14:850-859.
28. Serrano-Fernandez P., et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 2010, 43:172-178.
29. Buttmann M., et al. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J. Neuroimmunol. 2004, 156:195-203.
30. Haak S., et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 2009, 119:61-69.
31. Boniface K., et al. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J. Immunol. 2010, 185:679-687.
32. Comabella M., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
33. Gomez-Rodriguez J., et al. Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase. Immunity 2009, 31:587-597.
34. Genovese M.C., et al. A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Res. Ther. 2004, 6:R73-R77.
35. Mannon P.J., et al. Suppression of inflammation in ulcerative colitis by interferon-{beta}-1a is accompanied by inhibition of IL-13 production. Gut 2010, 60:449-455.
36. van Hamburg J.P., et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 2010, 63:73-83.
37. Shah K., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12:R53.
38. Fujishima S., et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch. Dermatol. Res. 2010, 302:499-505.
39. Watanabe H., et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J. Invest. Dermatol. 2009, 129:650-656.
40. Ishizu T., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
41. Lucchinetti C.F., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
42. Paul F., et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007, 4:e133.
43. Hengstman G.J., et al. Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult. Scler. 2007, 13:679-682.
44. Smith E., et al. IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J. Immunol. 2007, 179:8274-8279.
45. Zhang Z., et al. Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine 2009, 46:79-91.
46. Kroenke M.A., et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008, 205:1535-1541.
47. Liang S.C., et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 2007, 179:7791-7799.
48. Uzawa A., et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult. Scler. 2010, 16:1443-1452.
49. Wilson N.J., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007, 8:950-957.
50. Ortega C., et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 2009, 86:435-443.
51. Cargill M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 2007, 80:273-290.
52. Nair R.P., et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J. Invest. Dermatol. 2008, 128:1653-1661.
53. Chan J.R., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 2006, 203:2577-2587.
54. Krueger G.G., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 2007, 356:580-592.
55. Kimball A.B., et al. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J. Am. Acad. Dermatol. 2011.
56. Segal B.M., et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804.
57. Coimbra S., et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br. J. Dermatol. 2010, 163:1282-1290.
58. Hueber W., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2:52ra72.
59. Nestle F.O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005, 202:135-143.
60. Hida S., et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000, 13:643-655.
61. Seckin D., et al. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr. Dermatol. 2004, 21:577-579.
62. Imafuku S., et al. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br. J. Dermatol. 2007, 156:1367-1369.
63. Downs A.M., Dunnill M.G. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin. Exp. Dermatol. 2000, 25:351-352.
64. Horev A., Halevy S. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. Isr. Med. Assoc. J. 2009, 11:760-761.
65. La Mantia L., Capsoni F. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol. Sci. 2010, 31:337-339.
66. Lopez-Lerma I., et al. New-onset psoriasis in a patient treated with interferon beta-1a. Br. J. Dermatol. 2009, 160:716-717.
67. Webster G.F., et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J. Am. Acad. Dermatol. 1996, 34:365-367.
68. Navne J.E., et al. [Activation of psoriasis in patients undergoing treatment with interferon-beta]. Ugeskr. Laeger 2005, 167:2903-2904.
69. Harrington L.E., et al. Expanding the effector CD4 T cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 2006, 18:349-356.
70. Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J. Neuroimmunol. 1992, 40:211-218.
71. Bettelli E., et al. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004, 200:79-87.
72. Panitch H.S., et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
73. Ferber I.A., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 1996, 156:5-7.
74. Harrington L.E., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
75. Ke Y., et al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J. Immunol. 2009, 182:3183-3190.
76. Wensky A., et al. The role of IFN-gamma in the production of Th2 subpopulations: implications for variable Th2-mediated pathologies in autoimmunity. J. Immunol. 2001, 167:3074-3081.